Ashika Ahmed, MD
Bellerophon Therapeutics
11
0
3
N/A
0
4
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+3 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (11)
Showing 10 of 11 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Meral Boşnak Güçlü, Prof. Dr.
Gazi University
Shared therapeutic areas:
Seetha Shankaran, MD
Wayne State University
Shared therapeutic areas:
Dale L. Phelps, MD
University of Rochester
Shared therapeutic areas:
Abhik Das, PhD
RTI International
Shared therapeutic areas:
Michele C. Walsh, MD MS
Case Western Reserve University, Rainbow Babies and Children's Hospital
Shared therapeutic areas:
Talant M Sooronbaev, MD
National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan
Shared therapeutic areas:
Neil N. Finer, MD
University of California, San Diego
Shared therapeutic areas:
Edward F. Donovan, MD
Children's Hospital Medical Center, Cincinnati
Shared therapeutic areas:
Christelle Haziza, PhD
Philip Morris Products S.A.
Shared therapeutic areas:
Barbara J. Stoll, MD
Emory University
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (11)
Showing 11 of 11 trials
A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH
IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction
Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)
Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD
Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric
Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19
Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis
All 11 trials loaded